InvestSMART

Cambium Bio Limited (ASX: CMB) - Announcements

- Current share price for CMB : $0.430

ASX company news and announcements for Cambium Bio Limited (CMB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cambium Bio Limited (CMB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cambium Bio Limited (CMB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cambium Bio Limited (CMB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$12 Notice of ceasing to be a substantial holder 11 Apr 2025 3:05PM $0.280 $0.430 risen by 53.57%
$12 Cambium Bio - Release of Shares from Escrow 21 Mar 2025 6:38PM $0.350 $0.430 risen by 22.86%
$12 Notice of change of interests of substantial holder-CMB 18 Mar 2025 6:07PM $0.350 $0.430 risen by 22.86%
$12 FDA Approves Cambium Bio's Potency Assay Strategy for Elate 18 Mar 2025 10:58AM $0.350 $0.430 risen by 22.86%
$12 Change of Directors Interest Notice 12 Mar 2025 6:11PM $0.350 $0.430 risen by 22.86%
$12 Notification regarding unquoted securities - CMB 12 Mar 2025 4:37PM $0.350 $0.430 risen by 22.86%
$12 Application for quotation of securities - CMB 12 Mar 2025 4:08PM $0.350 $0.430 risen by 22.86%
$12 Mr Chiu - Director Appointment and Appedix 3X 7 Mar 2025 11:05AM $0.350 $0.430 risen by 22.86%
$12 Results of General Meeting 4 Mar 2025 4:25PM $0.300 $0.430 risen by 43.33%
$12 Response to queries re Appendices 3X and 3Z 3 Mar 2025 12:26PM $0.390 $0.430 risen by 10.26%
$12 Update - Proposed issue of securities - CMB 28 Feb 2025 10:56AM $0.400 $0.430 risen by 7.50%
$12 Half Year Report and Accounts 27 Feb 2025 6:25PM $0.400 $0.430 risen by 7.50%
$12 FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol 25 Feb 2025 10:15AM $0.390 $0.430 risen by 10.26%
$12 Final Director Interest Notice-Graham Vesey 17 Feb 2025 7:10PM $0.380 $0.430 risen by 13.16%
$12 Initial and Final Director Interest Notices-Chandra Bala 17 Feb 2025 7:09PM $0.380 $0.430 risen by 13.16%
$12 Placement Shares Cleansing Notice 13 Feb 2025 1:28PM $0.380 $0.430 risen by 13.16%
$12 Application for quotation of securities - CMB 13 Feb 2025 1:27PM $0.380 $0.430 risen by 13.16%
$12 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2025 1:21PM $0.390 $0.430 risen by 10.26%
$12 Notice of General Meeting/Proxy Form 30 Jan 2025 11:14AM $0.390 $0.430 risen by 10.26%
$12 Change in substantial holding 7 Jan 2025 10:42AM $0.450 $0.430 fallen by 4.44%
$12 Placement Shares Cleansing Notice 12 Dec 2024 3:30PM $0.540 $0.430 fallen by 20.37%
$12 Application for quotation of securities - CMB 12 Dec 2024 3:29PM $0.540 $0.430 fallen by 20.37%
$12 FDA Grants Fast Track Designation 9 Dec 2024 10:56AM $0.625 $0.430 fallen by 31.20%
$12 Proposed issue of securities - CMB 5 Dec 2024 1:07PM $0.625 $0.430 fallen by 31.20%
$12 Cambium Bio Successfully Closes A$3.0M Financing Round 5 Dec 2024 10:11AM $0.640 $0.430 fallen by 32.81%

51 - 75 of 123 results

Page 3 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.